Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuaki Sagara

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Breast Cancer (Tokyo, Japan)|February 18, 2025
A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancerReiki Nishimura, Yasuaki Sagara, Reiko Mitsueda, et al.
Breast Cancer Research and Treatment|August 24, 2017
Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinomaKyoko Kikuchi, Keely May McNamara, Yasuhiro Miki, et al.
Breast Cancer (Tokyo, Japan)|April 21, 2025
Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause statusTakaaki Konishi, Hiraku Kumamaru, Naoki Niikura, et al.
BMC Cancer|September 14, 2023
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)Sung-Hsin Kuo, Ling-Ming Tseng, Shou-Tung Chen, et al.
British Journal of Cancer|April 3, 2020
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 studyHirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, et al.
Breast Cancer (Tokyo, Japan)|February 5, 2025
Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expressionMasayuki Nagahashi, Hiraku Kumamaru, Naoko Kinukawa, et al.
Breast Cancer (Tokyo, Japan)|February 18, 2021
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort studyKiyo Tanaka, Norikazu Masuda, Naoki Hayashi, et al.
Breast Cancer (Tokyo, Japan)|June 12, 2026
Annual report of national clinical database-breast cancer registry in 2023: systemic therapy for small breast cancerShinsuke Sasada, Hiraku Kumamaru, Naoko Kinukawa, et al.
Breast Cancer Research and Treatment|January 5, 2024
Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinomaSaki Nakagawa, Minoru Miyashita, Ichiro Maeda, et al.
Breast Cancer (Tokyo, Japan)|February 14, 2018
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)Shoichiro Ohtani, Takahiro Nakayama, Tetsuhiro Yoshinami, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Breast Cancer (Tokyo, Japan)|February 18, 2025
A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancerReiki Nishimura, Yasuaki Sagara, Reiko Mitsueda, et al.
Breast Cancer Research and Treatment|August 24, 2017
Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinomaKyoko Kikuchi, Keely May McNamara, Yasuhiro Miki, et al.
Breast Cancer (Tokyo, Japan)|April 21, 2025
Annual report of National Clinical Database-Breast Cancer Registry in 2021: characteristics categorized by body mass index and menopause statusTakaaki Konishi, Hiraku Kumamaru, Naoki Niikura, et al.
BMC Cancer|September 14, 2023
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)Sung-Hsin Kuo, Ling-Ming Tseng, Shou-Tung Chen, et al.
British Journal of Cancer|April 3, 2020
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 studyHirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, et al.
Breast Cancer (Tokyo, Japan)|February 5, 2025
Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expressionMasayuki Nagahashi, Hiraku Kumamaru, Naoko Kinukawa, et al.
Breast Cancer (Tokyo, Japan)|February 18, 2021
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort studyKiyo Tanaka, Norikazu Masuda, Naoki Hayashi, et al.
Breast Cancer (Tokyo, Japan)|June 12, 2026
Annual report of national clinical database-breast cancer registry in 2023: systemic therapy for small breast cancerShinsuke Sasada, Hiraku Kumamaru, Naoko Kinukawa, et al.
Breast Cancer Research and Treatment|January 5, 2024
Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinomaSaki Nakagawa, Minoru Miyashita, Ichiro Maeda, et al.
Breast Cancer (Tokyo, Japan)|February 14, 2018
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)Shoichiro Ohtani, Takahiro Nakayama, Tetsuhiro Yoshinami, et al.
Pageof 14